Evolocumab reduced total cardiovascular events in high-risk patients
Evolocumab reduced the combined rate of coronary heart disease deaths, heart attacks and strokes caused by blocked blood flow by 27% versus placebo.Evolocumab reduced the combined rate of coronary heart disease deaths, heart attacks and strokes caused by blocked blood flow by 27% versus placebo.